抗パーキンソン病薬の世界市場レポート 2025年

抗パーキンソン病薬市場規模は、今後数年間で力強い成長が見込まれます。2029年には137億3,000万米ドルに成長し、CAGRは5.5%となります。予測期間の成長は、認知度の向上、バイオテクノロジーの進歩、新興市場に起因しています。予測期間の主な動向には、研究開発への投資、個別化医療、疾患修飾療法、薬剤再利用、遠隔医療と遠隔モニタリング、バイオシミラー、共同研究などがあります。

抗パーキンソン病薬の需要拡大が予想される背景には、老年人口の増加とパーキンソン病（PD）の症例数の増加があります。PDは一般的に60歳以上で診断されることが多く、高齢者にとっては特に関心の高い疾患です。例えば、世界保健機関（WHO）のデータによると、世界全体で60歳以上の高齢者の割合は2030年までに6人に1人に達し、この数字は2050年までに倍増して21億人に達すると予測されています。同様に、英国議会の下院図書館のデータによると、英国の高齢者人口は大幅に増加し、2043年までに総人口の24％（1,740万人）を占めると予想されています。高齢者におけるPDの有病率が高いことから、このような高齢者への人口動態の変化は、抗パーキンソン病薬の需要増加の重要な原動力となっています。

抗パーキンソン病薬市場の成長が期待される背景には、精神疾患の増加があります。メンタルヘルス障害は、個人の認知、感情調節、行動における臨床的に重大な障害を表し、多くの場合、生活のさまざまな領域における苦痛や機能障害を伴う。精神疾患の増加は抗パーキンソン病薬市場に直接的な影響を与えており、これらの薬剤はこれらの疾患の緩和や治療に重要な役割を果たしています。例えば、英国のHealth and Social Care Information Centreのデータによると、精神障害が疑われる17～19歳の割合は顕著に増加しており、2021年の17.4%から2022年には25.7%に上昇します。このデータは、精神疾患の蔓延が拡大していることを示しており、それが抗パーキンソン病薬の需要を牽引しています。この2つの要因の関連性は、パーキンソン病やその関連疾患に罹患している人々のメンタルヘルスニーズに対応する抗パーキンソン病薬の重要性を強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界抗パーキンソン病薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の抗パーキンソン病薬市場：成長率分析
• 世界の抗パーキンソン病薬市場の実績：規模と成長, 2019-2024
• 世界の抗パーキンソン病薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界抗パーキンソン病薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗パーキンソン病薬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• レボドパまたはカルビドパ
• ドーパミン受容体作動薬
• モノアミン酸化酵素B型（MAO-B）阻害剤
• カテコール-O-メチルトランスフェラーゼ（COMT）阻害剤
• 抗コリン薬
• その他の薬物
• 世界の抗パーキンソン病薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射
• 経皮
• 世界の抗パーキンソン病薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の抗パーキンソン病薬市場レボドパまたはカルビドパの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 即放性レボドパまたはカルビドパ
• 徐放性レボドパまたはカルビドパ
• 世界の抗パーキンソン病薬市場ドーパミン受容体作動薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プラミペキソール
• ロピニロール
• ロチゴチン
• 世界の抗パーキンソン病薬市場モノアミン酸化酵素B型（MAO-B）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• セレギリン
• ラサギリン
• サフィナミド
• 世界の抗パーキンソン病薬市場カテコール-O-メチルトランスフェラーゼ（COMT）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エンタカポン
• トルカポン
• 世界の抗パーキンソン病薬市場抗コリン薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベンツトロピン
• トリヘキシフェニジル
• 世界の抗パーキンソン病薬市場その他の医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アマンタジン
• アポモルフィン

第7章 地域別・国別分析

• 世界の抗パーキンソン病薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の抗パーキンソン病薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗パーキンソン病薬市場：競合情勢
• 抗パーキンソン病薬市場：企業プロファイル
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck Co. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• UCB S.A
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Mylan NV
• C.H. Boehringer Sohn AG & Co. KG
• Orion Pharma Ltd.
• ACADIA Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Ltd.
• Wockhardt Ltd.
• Reddy's Laboratories Ltd.
• Intas Pharmaceuticals Ltd.
• US WorldMeds LLC
• Zydus Lifesciences Limited
• Chemical Industrial & Pharmaceutical Laboratories Ltd.
• Strides Shasun Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 抗パーキンソン病薬市場2029：新たな機会を提供する国
• 抗パーキンソン病薬市場2029：新たな機会を提供するセグメント
• 抗パーキンソン病薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Anti-Parkinson drugs are medications primarily utilized for the treatment of Parkinson's disease. It's important to note that these drugs are not psychiatric medications and are not intended for the treatment of mental health issues. However, in some cases, a doctor or psychiatrist may recommend the use of these medications in addition to antipsychotics to mitigate certain negative effects associated with the latter.

The main categories of anti-Parkinson drugs include levodopa/carbidopa, dopamine receptor agonists, monoamine oxidase type B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, anticholinergics, and other drugs. Catechol-O-methyltransferase (COMT) inhibitors represent a specific class of drugs used in conjunction with carbidopa-levodopa therapy to manage Parkinson's disease symptoms effectively. These medications can be administered through various routes, including oral, injection, and transdermal methods, and they are typically dispensed through hospital pharmacies, retail pharmacies, and online pharmacies.

The anti-Parkinson drugs market research report is one of a series of new reports from The Business Research Company that provides anti-Parkinson drugs market statistics, including anti-Parkinson drugs industry global market size, regional shares, competitors with an anti-Parkinson drugs market share, detailed anti-Parkinson drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-Parkinson drugs industry. This anti-Parkinson drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-parkinson drugs market size has grown strongly in recent years. It will grow from $10.37 billion in 2024 to $11.08 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to aging population, increasing disease prevalence, healthcare infrastructure, advancements in research.

The anti-parkinson drugs market size is expected to see strong growth in the next few years. It will grow to $13.73 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to growing awareness, biotechnological advancements, emerging markets. Major trends in the forecast period include investment in r&d, personalized medicine, disease-modifying therapies, drug repurposing, telemedicine and remote monitoring, biosimilars, research collaborations.

The anticipated growth in the demand for anti-Parkinson drugs is driven by the increasing geriatric population and the rising number of cases of Parkinson's disease (PD). PD is commonly diagnosed in individuals over the age of 60, making it a particular concern for the elderly population. For example, data from the World Health Organization indicates that globally, the proportion of individuals aged 60 or older is expected to reach 1 in 6 by 2030, and this figure is projected to double by 2050, reaching 2.1 billion individuals in this age group. Similarly, data from the UK Parliament's House of Commons Library reveals that the elderly population in the UK is expected to grow significantly, accounting for 24% of the total population (17.4 million people) by 2043. This demographic shift towards an older population is a key driver of the increasing demand for anti-Parkinson drugs, given the higher prevalence of PD in the elderly.

The expected growth in the anti-Parkinson drugs market is being propelled by the increasing incidence of mental health disorders. Mental health disorders represent a clinically significant impairment in an individual's cognitive, emotional regulation, or behavior, often associated with distress and functional impairment in various areas of life. The rise in mental health disorders has a direct impact on the anti-Parkinson drugs market, as these drugs play a crucial role in mitigating and treating these disorders. For example, data from the Health and Social Care Information Centre in the UK reveals a notable increase in the proportion of 17- to 19-year-olds with suspected mental disorders, rising from 17.4% in 2021 to 25.7% in 2022. This data illustrates the growing prevalence of mental health disorders, which, in turn, drives the demand for anti-Parkinson drugs. The connection between these two factors underscores the importance of anti-Parkinson drugs in addressing the mental health needs of individuals affected by Parkinson's disease and related conditions.

The anticipated growth of the anti-Parkinson's drug market may face limitations due to the high cost associated with the treatment of Parkinson's disease. According to statistics from the Michael J. Fox Foundation for Parkinson's Research, the economic burden of Parkinson's disease is on the rise and affects patients, their families, and the federal government. In the United States, the overall cost of Parkinson's disease amounts to $51.9 billion annually, with $25.4 billion allocated to direct medical costs, including expenses related to hospitalization and medication. This significant financial burden on individuals, families, and healthcare systems underscores the high cost of managing Parkinson's disease. Consequently, the expense of treating the condition can potentially restrict access to anti-Parkinson drugs and influence the market's growth dynamics. Finding cost-effective solutions and approaches to Parkinson's disease treatment will be a key consideration for stakeholders in the anti-Parkinson's drug market.

Major companies in the anti-Parkinson drugs market are increasingly focused on developing advanced therapeutic solutions to address challenges such as motor fluctuations and dyskinesia, which complicate Parkinson's disease treatment and impact patient well-being. For example, in January 2024, AbbVie Inc., a US-based pharmaceutical company, launched PRODUODOPA, the first subcutaneous 24-hour infusion therapy for advanced Parkinson's disease. PRODUODOPA (foslevodopa/foscarbidopa) specifically targets severe motor fluctuations and dyskinesia in patients for whom other treatments have failed. The therapy continuously delivers levodopa, potentially increasing "on" time and improving symptom control.

A significant trend in the anti-Parkinson drugs market is the increased investment from both government and corporate sources in research and development for drugs related to Parkinson's disease. For example, in August 2022, the Parkinson's Foundation, a prominent national organization in the United States, announced a substantial investment of $5.7 million into 33 research projects. This funding is aimed at accelerating cutting-edge research in the field of Parkinson's disease. By providing research grants, the foundation supports scientists in conducting innovative studies on various aspects of Parkinson's disease. The ultimate goal is to develop new therapies, treatments, and, ideally, a cure for the approximately 10 million individuals worldwide who are affected by this debilitating neurological condition. As a result, the increased investments in Parkinson's drug development are expected to be a driving force in the anti-Parkinson drugs market.

In October 2023, AbbVie Inc., a US-based pharmaceutical company, acquired Mitokinin for $110 million. This acquisition is part of AbbVie's strategy to strengthen its neuroscience pipeline and expand treatment options for Parkinson's disease (PD) patients. Mitokinin, a US-based biotechnology company, specializes in developing treatments for Parkinson's disease.

Major companies operating in the anti-parkinson drugs market include GlaxoSmithKline plc, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., ACADIA Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Axcan Pharma Inc., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, M Somerset Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.

North America was the largest region in the anti-Parkinson drugs market in 2024. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anti-parkinson drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-parkinson drugs market consists of sales of catechol-O-methyl transferase [COMT] inhibitors, anticholinergic drugs, and amantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-Parkinson Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-parkinson drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-parkinson drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anti-parkinson drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs Class: Levodopa Or Carbidopa; Dopamine Receptor Agonists; Monoamine Oxidase Type B (MAO-B) Inhibitors; Catechol-O-Methyltransferase (COMT)-inhibitors; Anticholinergics; Other Drugs
• 2) By Route of Administration: Oral; Injection; Transdermal
• 3) By Distribution Channel: Hospital Pharmacies; Retailer Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa; Extended-Release Levodopa Or Carbidopa
• 2) By Dopamine Receptor Agonists: Pramipexole; Ropinirole; Rotigotine
• 3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline; Rasagiline; Safinamide
• 4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone; Tolcapone
• 5) By Anticholinergics: Benztropine; Trihexyphenidyl
• 6) By Other Drugs: Amantadine; Apomorphine
• Companies Mentioned: GlaxoSmithKline plc; Pfizer Inc.; Merck Co.; Novartis AG; F. Hoffmann-La Roche AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anti-Parkinson Drugs Market Characteristics

3. Anti-Parkinson Drugs Market Trends And Strategies

4. Anti-Parkinson Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Anti-Parkinson Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Anti-Parkinson Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Anti-Parkinson Drugs Market Growth Rate Analysis
• 5.4. Global Anti-Parkinson Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Anti-Parkinson Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Anti-Parkinson Drugs Total Addressable Market (TAM)

6. Anti-Parkinson Drugs Market Segmentation

• 6.1. Global Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Levodopa Or Carbidopa
• Dopamine Receptor Agonists
• Monoamine Oxidase Type B (MAO-B) Inhibitors
• Catechol-O-Methyltransferase (COMT)-inhibitors
• Anticholinergics
• Other Drugs
• 6.2. Global Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injection
• Transdermal
• 6.3. Global Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retailer Pharmacies
• Online Pharmacies
• 6.4. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Levodopa Or Carbidopa, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immediate-Release Levodopa Or Carbidopa
• Extended-Release Levodopa Or Carbidopa
• 6.5. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Dopamine Receptor Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pramipexole
• Ropinirole
• Rotigotine
• 6.6. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Monoamine Oxidase Type B (MAO-B) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selegiline
• Rasagiline
• Safinamide
• 6.7. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Catechol-O-Methyltransferase (COMT)-Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Entacapone
• Tolcapone
• 6.8. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Anticholinergics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Benztropine
• Trihexyphenidyl
• 6.9. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amantadine
• Apomorphine

7. Anti-Parkinson Drugs Market Regional And Country Analysis

• 7.1. Global Anti-Parkinson Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Anti-Parkinson Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anti-Parkinson Drugs Market

• 8.1. Asia-Pacific Anti-Parkinson Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anti-Parkinson Drugs Market

• 9.1. China Anti-Parkinson Drugs Market Overview
• 9.2. China Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anti-Parkinson Drugs Market

• 10.1. India Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anti-Parkinson Drugs Market

• 11.1. Japan Anti-Parkinson Drugs Market Overview
• 11.2. Japan Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anti-Parkinson Drugs Market

• 12.1. Australia Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anti-Parkinson Drugs Market

• 13.1. Indonesia Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anti-Parkinson Drugs Market

• 14.1. South Korea Anti-Parkinson Drugs Market Overview
• 14.2. South Korea Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anti-Parkinson Drugs Market

• 15.1. Western Europe Anti-Parkinson Drugs Market Overview
• 15.2. Western Europe Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anti-Parkinson Drugs Market

• 16.1. UK Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anti-Parkinson Drugs Market

• 17.1. Germany Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anti-Parkinson Drugs Market

• 18.1. France Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anti-Parkinson Drugs Market

• 19.1. Italy Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anti-Parkinson Drugs Market

• 20.1. Spain Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anti-Parkinson Drugs Market

• 21.1. Eastern Europe Anti-Parkinson Drugs Market Overview
• 21.2. Eastern Europe Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anti-Parkinson Drugs Market

• 22.1. Russia Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anti-Parkinson Drugs Market

• 23.1. North America Anti-Parkinson Drugs Market Overview
• 23.2. North America Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anti-Parkinson Drugs Market

• 24.1. USA Anti-Parkinson Drugs Market Overview
• 24.2. USA Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anti-Parkinson Drugs Market

• 25.1. Canada Anti-Parkinson Drugs Market Overview
• 25.2. Canada Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anti-Parkinson Drugs Market

• 26.1. South America Anti-Parkinson Drugs Market Overview
• 26.2. South America Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anti-Parkinson Drugs Market

• 27.1. Brazil Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anti-Parkinson Drugs Market

• 28.1. Middle East Anti-Parkinson Drugs Market Overview
• 28.2. Middle East Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anti-Parkinson Drugs Market

• 29.1. Africa Anti-Parkinson Drugs Market Overview
• 29.2. Africa Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anti-Parkinson Drugs Market Competitive Landscape And Company Profiles

• 30.1. Anti-Parkinson Drugs Market Competitive Landscape
• 30.2. Anti-Parkinson Drugs Market Company Profiles
  • 30.2.1. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

31. Anti-Parkinson Drugs Market Other Major And Innovative Companies

• 31.1. UCB S.A
• 31.2. Teva Pharmaceutical Industries Ltd.
• 31.3. AbbVie Inc.
• 31.4. Mylan NV
• 31.5. C.H. Boehringer Sohn AG & Co. KG
• 31.6. Orion Pharma Ltd.
• 31.7. ACADIA Pharmaceuticals Inc.
• 31.8. Sun Pharmaceutical Industries Ltd.
• 31.9. Wockhardt Ltd.
• 31.10. Reddy's Laboratories Ltd.
• 31.11. Intas Pharmaceuticals Ltd.
• 31.12. US WorldMeds LLC
• 31.13. Zydus Lifesciences Limited
• 31.14. Chemical Industrial & Pharmaceutical Laboratories Ltd.
• 31.15. Strides Shasun Ltd.

32. Global Anti-Parkinson Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti-Parkinson Drugs Market

34. Recent Developments In The Anti-Parkinson Drugs Market

35. Anti-Parkinson Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Anti-Parkinson Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Anti-Parkinson Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Anti-Parkinson Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer